San­doz un­veiled a di­rect-to-con­sumer plat­form, start­ing off with a sin­gle med­ica­tion for now as the gener­ic drug­mak­er adopts a sys­tem that sev­er­al brand-name man­u­fac­tur­ers are...

US Dis­trict Court Judge Daniel Domeni­co in Col­orado grant­ed Am­gen's pre­lim­i­nary in­junc­tion to stop a 70% price cap on its block­buster au­toim­mune drug En­brel, ar­gu­ing that...

Ot­su­ka on Thurs­day re­port­ed new long-term da­ta that it hopes will con­vert an ac­cel­er­at­ed ap­proval to a full green light in kid­ney dis­ease.

The com­pa­ny...

Less than six months af­ter lin­ing up one of the largest biobucks pack­ages in in­dus­try his­to­ry, As­traZeneca is re­turn­ing to the same Chi­nese part­ner for...

Rev­o­lu­tion Med­i­cines on Thurs­day gave a first look at the ear­ly-stage da­ta that led it to plan a Phase 3 tri­al com­bin­ing two KRAS drugs...

Roche’s lung can­cer drug can­di­date di­vara­sib has beat­en mar­ket­ed drugs from Am­gen and Bris­tol My­ers Squibb in a head-to-head tri­al. Full da­ta haven't yet emerged...

Armed with im­pres­sive Phase 3 da­ta, Bright­Gene is tak­ing its obe­si­ty shot to Chi­nese reg­u­la­tors. It ex­pects tri­al da­ta in the West to be even...